Weight gain with valproate or carbamazepine - A reappraisal

Seizure

Volumn 6, Issue 2, 1997, Pages 121-125

  Easter, Derrick ^a,c   O'Bryan Tear, C Gillies ^a   Verity, Christopher ^b  

^a Sanofi Winthrop Limited   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c Sanofi Winthrop Limited   (United Kingdom)

Author keywords

Carbamazepine; Epilepsy; Sodium valproate; Weight gain

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID;

ADOLESCENT; ARTICLE; BODY WEIGHT DISORDER; CHILD; DRUG USE; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; WEIGHT GAIN;

EID: 0031005862     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(97)80065-9     Document Type: Article

References (14)

1. Covanis, A., Gupta, A.K. and Jeavons, P.M. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982: 23: 693-720.
2. Richens, A., Davidson, D.L.W., Cartlidge, N.E.F. and Easter, D.J., on behalf of the Adult EPITEG Study Group. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 1994; 57: 682-687.
3. Verity, C.M., Hosking, G. and Easter, D.J., on behalf of the Paediatric EPITEG Collaborative Group. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Developmental Medicine and Child Neurology 1995; 37: 97-108.
4. de Silva, M., MacArdle, B., McGowan, M. et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-713.
5. Laljee, H.C.K. and Parsonage, M.J. Unwanted effects of sodium valproate in the treatment of adult patients with epilepsy. In: The Place of Sodium Valproate in the Treatment of Epilepsy: Royal Society of Medicine International Congress and Symposium No. 30. London, Academic Press and Royal Society of Medicine, 1980; pp. 141-158.
6. Dam, M. and Gram, L. Weight changes in epileptic patients treated with valproate. Presented at: Danish Epilepsy Society Meeting: Valproate in the treatment of seizures. May 1981: pp. 83-86.
7. Egger, J. and Brett, E. M. Effects of sodium valproate in 100 children with special reference to weight. British Medical Journal 1981; 283: 577-581.
8. Cronk, C.E. and Roche, A.F. Race- and sex-specific reference data for triceps and subscapular skinfolds and weight/stature. American Journal of Clinical Nutrition 1982; 35: 347-354.
9. Breum, L., Astrup, A., Gram, L. et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666-670.
10. Vorum, H., Gram, L. and Honoré, B. Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Research 1993; 16: 55-64.
11. Vorum, H., Andersen, S. and Brodersen, R. Valproate competes with palmitate for binding to serum albumin. Epilepsia 1989; 30: 370-373.
12. Brodersen, R., Jørgensen, N., Vorum, H. and Krukow, N. Valproate and palmitate binding to human serum albumin: an hypothesis on obesity. Molecular Pharmacology 1990; 37: 704-709.
13. Dinnesen, H., Gram, L., Anderson, T. and Dam, M. Weight gain during treatment with valproate. Acta Neurologica Scandinavica 1984; 70: 65-69.
14. Mattson, R.H., Cramer, J.A. and Collins, J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. New England Journal of Medicine 1992; 327: 765-771.